Marcin Kortylewski
Overview
Explore the profile of Marcin Kortylewski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
6500
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DeFranciscis V, Amabile G, Kortylewski M
Mol Ther
. 2025 Mar;
PMID: 40045578
Oligonucleotide therapeutics (ONTs) represent a rapidly evolving modality for cancer treatment, capitalizing on their ability to modulate gene expression with high specificity. With more than 20 nucleic acid-based therapies that...
2.
Chen F, Zhao D, Xu Y, Zhang Y, Chen M, Pathak K, et al.
Nat Commun
. 2025 Feb;
16(1):1253.
PMID: 39893171
We reported that an acquired miR-142 deficit transforms chronic phase (CP) chronic myeloid leukemia (CML) leukemic stem cells (LSCs) into blast crisis (BC) LSCs. Given the role of miR-142 in...
3.
Zhang C, Huang R, Ren L, Martincuks A, Song J, Kortylewski M, et al.
Mol Ther Nucleic Acids
. 2024 Dec;
35(4):102357.
PMID: 39618825
Immune checkpoint blockade (ICB) therapy has significantly benefited patients with several types of solid tumors and some lymphomas. However, many of the treated patients do not have a durable clinical...
4.
Wang D, Kaniowski D, Jacek K, Su Y, Yu C, Hall J, et al.
Mol Ther Nucleic Acids
. 2024 Aug;
35(3):102268.
PMID: 39171140
Acute myeloid leukemia (AML) cells resist differentiation stimuli despite high expression of innate immune receptors, such as Toll-like receptor 9 (TLR9). We previously demonstrated that targeting Signal Transducer and Activator...
5.
Ebrahimi H, Dizman N, Meza L, Malhotra J, Li X, Dorff T, et al.
Nat Med
. 2024 Jun;
30(9):2576-2585.
PMID: 38942995
Supplementation with CBM588, a bifidogenic live bacterial product, has been associated with improved clinical outcomes in persons with metastatic renal cell carcinoma (mRCC) receiving nivolumab and ipilimumab. However, its effect...
6.
Hall J, Zhang Z, Bhattacharya S, Wang D, Alcantara M, Liang Y, et al.
Mol Ther Nucleic Acids
. 2024 Feb;
35(1):102137.
PMID: 38384444
Decoy oligodeoxynucleotides (ODNs) allow targeting undruggable transcription factors, such as STAT3, but their limited potency and lack of delivery methods hampered translation. To overcome these challenges, we conjugated a STAT3-specific...
7.
Kalinski P, Kokolus K, Azrak R, Berezin M, Brentjens R, Czerniecki B, et al.
Wiad Lek
. 2024 Jan;
76(12):2543-2555.
PMID: 38290016
Marie Skłodowska-Curie Symposia on Cancer Research and Care (MSCS-CRC) promote collaborations between cancer researchers and care providers in the United States, Canada and Central and Eastern European Countries (CEEC), to...
8.
Alcantara M, Tang W, Wang D, Kaniowski D, Kang E, Dizman N, et al.
Front Immunol
. 2024 Jan;
14:1274781.
PMID: 38259453
Introduction: Immune checkpoint blockade (ICB) improved clinical outcomes in renal and bladder cancer patients, but the response rates remain limited especially in metastatic disease. While STAT3 transcription factor is well-known...
9.
Zhang B, Zhao D, Chen F, Frankhouser D, Wang H, Pathak K, et al.
Nat Commun
. 2023 Sep;
14(1):5325.
PMID: 37658085
The mechanisms underlying the transformation of chronic myeloid leukemia (CML) from chronic phase (CP) to blast crisis (BC) are not fully elucidated. Here, we show lower levels of miR-142 in...
10.
Zhang C, Huang R, Ren L, Song J, Kortylewski M, Swiderski P, et al.
bioRxiv
. 2023 Aug;
PMID: 37645787
Immune checkpoint blockade (ICB) therapy has significantly benefited patients with several types of solid tumors and some lymphomas. However, many of the treated patients do not have durable clinical response....